Template:Prazosin: Difference between revisions

Jump to navigation Jump to search
(Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8...")
 
No edit summary
 
(One intermediate revision by the same user not shown)
Line 2: Line 2:
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Prazosin|{{fontcolor|#6C7B8B|Prazosin}}]]'''''
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Prazosin|{{fontcolor|#6C7B8B|Prazosin}}]]'''''
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | PRAZOSIN<sup>®</sup>, MINIPRESS<sup>®</sup> FDA Package Insert
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Prazosin<sup>®</sup>, Minipress<sup>®</sup> FDA Package Insert
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin indications and usage|Indications and Usage]]
Line 8: Line 8:
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin dosage and administration|Dosage and Administration]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin dosage forms and strengths|Dosage Forms and Strengths]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin contraindications|Contraindications]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin contraindications|Contraindications]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin warnings|Warnings]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin warnings and precautions|Warnings and Precautions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin precautions|Precautions]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin adverse reactions|Adverse Reactions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin adverse reactions|Adverse Reactions]]
Line 27: Line 27:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin nonclinical toxicology|Nonclinical Toxicology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin nonclinical toxicology|Nonclinical Toxicology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin how supplied storage and handling|How Supplied/Storage and Handling]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Prazosin how supplied storage and handling|How Supplied/Storage and Handling]]

Latest revision as of 19:42, 12 March 2014